Pharmacists in Bainbridge Island, Washington


11 Pharmacists found in Bainbridge Island
female pharmacist

Christine Mcguire, R. PH.


Pharmacist
253 High School Rd Ne, Bainbridge Island, WA 98110
206-842-0127     206-780-0731

female pharmacist

Ms. Heidi I Sampson, RPH


Pharmacist
253 High School Rd Ne, Bainbridge Island, WA 98110
206-842-0127     206-780-0731

female pharmacist

Jinjoo Kang


Pharmacist
253 High School Rd Ne, Bainbridge Island, WA 98110
206-842-0127    



male pharmacist

Mr. Justin D Ausmeier, PHARMACIST


Pharmacist
301 High School Rd Ne, Bainbridge Island, WA 98110
206-842-4065     206-780-2781

female pharmacist

Mrs. Karin Nina Schmugge, PHARMD


Pharmacist
253 High School Rd Ne, Bainbridge Island, WA 98110
206-842-7197    

female pharmacist

Lindsay Lee Holmson, PHARMD


Pharmacist
301 High School Rd Ne, Bainbridge Island, WA 98110
206-842-4065    

female pharmacist

Miss Mallory Anne Farrar, PHARMD


Pharmacist
8191 Ne Selfors Ln, Bainbridge Island, WA 98110
206-850-7914    

female pharmacist

Melanie Anne Solvie


Pharmacist
253 High School Rd Ne, Bainbridge Island, WA 98110
206-842-0127     206-780-0731

female pharmacist

Stacy Elizabeth Johnson, PHARMD


Pharmacist
301 High School Rd Ne, Bainbridge Island, WA 98110
206-842-4065     206-780-2781

male pharmacist

Stewart Umbela, PHARMD


Pharmacist
1315 Wintergreen Ln Ne, Bainbridge Island, WA 98110
206-317-8521    

female pharmacist

Vicki Runquist


Pharmacist - Clinician (PhC)/ Clinical Pharmacy Specialist
1344 Wintergreen Ln Ne, Bainbridge Island, WA 98110
206-842-5632     206-842-5992


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.